Teva Pharmaceutical Industries Ltd. $TEVA is Menora Mivtachim Holdings LTD.'s 8th Largest Position

Key Points

• Menora Mivtachim Holdings LTD. increased its stake in Teva Pharmaceutical Industries by 2.8% during Q1, now holding approximately 29.2 million shares valued at $448.6 million.
• Several institutional investors, including the State of New Jersey Common Pension Fund D and Aberdeen Group plc, have also raised their stakes in Teva Pharmaceutical Industries, reflecting significant interest from institutional investors.
• Analysts have recently upgraded their ratings on Teva, with JPMorgan raising its rating to "overweight" and a price target increase to $23, while others have issued "buy" ratings providing a consensus target price of $24.71.

Menora Mivtachim Holdings LTD. boosted its position in Teva Pharmaceutical Industries Ltd. (NYSE:TEVA - Free Report) by 2.8% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,189,316 shares of the company's stock after purchasing an additional 808,074 shares during the quarter. Teva Pharmaceutical Industries comprises 2.9% of Menora Mivtachim Holdings LTD.'s investment portfolio, making the stock its 8th biggest position. Menora Mivtachim Holdings LTD. owned about 2.57% of Teva Pharmaceutical Industries worth $448,640,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also recently made changes to their positions in TEVA. Cerity Partners LLC raised its position in shares of Teva Pharmaceutical Industries by 15.2% during the 4th quarter. Cerity Partners LLC now owns 47,712 shares of the company's stock valued at $981,000 after buying an additional 6,311 shares in the last quarter. Townsquare Capital LLC raised its position in shares of Teva Pharmaceutical Industries by 2.1% during the 4th quarter. Townsquare Capital LLC now owns 40,162 shares of the company's stock valued at $885,000 after buying an additional 812 shares in the last quarter. Mariner LLC raised its position in shares of Teva Pharmaceutical Industries by 10.6% during the 4th quarter. Mariner LLC now owns 59,356 shares of the company's stock valued at $1,308,000 after buying an additional 5,689 shares in the last quarter. CreativeOne Wealth LLC purchased a new stake in shares of Teva Pharmaceutical Industries during the 4th quarter valued at $869,000. Finally, NewEdge Advisors LLC raised its position in shares of Teva Pharmaceutical Industries by 12.6% during the 4th quarter. NewEdge Advisors LLC now owns 35,482 shares of the company's stock valued at $782,000 after buying an additional 3,983 shares in the last quarter. Hedge funds and other institutional investors own 54.05% of the company's stock.

Teva Pharmaceutical Industries Trading Down 2.8%

Shares of TEVA traded down $0.5050 during trading hours on Tuesday, reaching $17.5550. 12,485,740 shares of the company traded hands, compared to its average volume of 12,708,362. The company's fifty day moving average price is $16.69 and its two-hundred day moving average price is $16.25. The company has a market capitalization of $20.13 billion, a price-to-earnings ratio of 7.22, a price-to-earnings-growth ratio of 1.07 and a beta of 0.62. The company has a quick ratio of 0.77, a current ratio of 1.06 and a debt-to-equity ratio of 2.45. Teva Pharmaceutical Industries Ltd. has a 12 month low of $12.47 and a 12 month high of $22.80.

Teva Pharmaceutical Industries (NYSE:TEVA - Get Free Report) last announced its earnings results on Wednesday, July 30th. The company reported $0.66 earnings per share for the quarter, beating analysts' consensus estimates of $0.64 by $0.02. The firm had revenue of $4.18 billion for the quarter, compared to analyst estimates of $4.34 billion. Teva Pharmaceutical Industries had a negative net margin of 0.95% and a positive return on equity of 46.10%. The company's revenue for the quarter was up .3% compared to the same quarter last year. During the same quarter in the previous year, the firm posted $0.61 EPS. Teva Pharmaceutical Industries has set its FY 2025 guidance at 2.500-2.600 EPS. Equities research analysts predict that Teva Pharmaceutical Industries Ltd. will post 2.5 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. JPMorgan Chase & Co. upgraded shares of Teva Pharmaceutical Industries from a "neutral" rating to an "overweight" rating and lifted their target price for the stock from $21.00 to $23.00 in a research report on Monday, May 12th. Wall Street Zen upgraded shares of Teva Pharmaceutical Industries from a "hold" rating to a "buy" rating in a research report on Saturday, July 26th. Truist Financial assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Wednesday, May 28th. They issued a "buy" rating and a $25.00 target price on the stock. Bank of America lifted their target price on shares of Teva Pharmaceutical Industries from $20.00 to $22.00 and gave the stock a "buy" rating in a research report on Thursday, May 8th. Finally, The Goldman Sachs Group assumed coverage on shares of Teva Pharmaceutical Industries in a research report on Friday, June 6th. They issued a "buy" rating and a $24.00 target price on the stock. Two research analysts have rated the stock with a Strong Buy rating and six have given a Buy rating to the company's stock. Based on data from MarketBeat.com, the stock presently has an average rating of "Buy" and an average target price of $24.71.

Insider Activity

In other news, EVP Matthew Shields sold 6,206 shares of Teva Pharmaceutical Industries stock in a transaction dated Tuesday, June 3rd. The shares were sold at an average price of $17.02, for a total transaction of $105,626.12. Following the sale, the executive vice president owned 9,989 shares of the company's stock, valued at approximately $170,012.78. The trade was a 38.32% decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider Placid Jover sold 6,053 shares of the business's stock in a transaction dated Friday, August 1st. The stock was sold at an average price of $15.16, for a total transaction of $91,763.48. Following the sale, the insider directly owned 6,774 shares in the company, valued at $102,693.84. The trade was a 47.19% decrease in their position. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 65,001 shares of company stock valued at $996,958. Corporate insiders own 0.55% of the company's stock.

About Teva Pharmaceutical Industries

Teva Pharmaceutical Industries Limited develops, manufactures, markets, and distributes generic medicines, specialty medicines, and biopharmaceutical products in North America, Europe, Israel, and internationally. It offers generic medicines in various dosage forms, such as tablets, capsules, injectables, inhalants, liquids, transdermal patches, ointments, and creams; sterile products, hormones, high-potency drugs, and cytotoxic substances in parenteral and solid dosage forms; and generic products with medical devices and combination products.